Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial

IMPORTANCE: Buprenorphine treatment for opioid use disorder may be improved by sustained-release formulations. OBJECTIVE: To determine whether treatment involving novel weekly and monthly subcutaneous (SC) buprenorphine depot formulations is noninferior to a daily sublingual (SL) combination of bupr...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Intern Med
Main Authors: Lofwall, Michelle R., Walsh, Sharon L., Nunes, Edward V., Bailey, Genie L., Sigmon, Stacey C., Kampman, Kyle M., Frost, Michael, Tiberg, Fredrik, Linden, Margareta, Sheldon, Behshad, Oosman, Sonia, Peterson, Stefan, Chen, Michael, Kim, Sonnie
Format: Artigo
Language:Inglês
Published: American Medical Association 2018
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6145749/
https://ncbi.nlm.nih.gov/pubmed/29799968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2018.1052
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items